Drug Trial Radar · NCT07901790
Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Feb 29, 2028
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Yonsei UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, prospective, randomized, active-controlled, single-blind (assessor-blinded) clinical trial aims to evaluate the efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells (ADMSCs) compared with active comparator hyaluronic acid (HA) in patients with Kellgren-Lawrence grade II to III knee osteoarthritis. A total of 165 participants across 3 centers (Severance Hospital, Seoul National University Hospital, Inha University Hospital) will be randomly allocated to either the ADMSC group (1.0 x 10\^8 cells, single injection) or the HA group (Synovian, 3 mL) in a 2:1 ratio and followed for 6 months post-injection.
Conditions
- Osteoarthritis
- Knee
- Knee Osteoarthritis
Interventions
Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs)Biological
Single intra-articular injection of 1.0 x 10\^8 culture-expanded autologous ADMSCs suspended in 3 mL cryopreservation medium (CryoStor 10) under ultrasound guidance.
Cross-linked Hyaluronic Acid (Synovian)Drug
Single intra-articular injection of 3 mL high molecular weight cross-linked hyaluronic acid (Synovian Inj., LG Chem) administered under ultrasound guidance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 6 MonthsTime frame: Baseline and 6 months post-injection
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Inha University Hospital
Incheon, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.